相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Real-world outcomes of regorafenib combined with immune checkpoint inhibitors in patients with advanced or metastatic microsatellite stable colorectal cancer: A multicenter study
Kaili Yang et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2022)
Nivolumab (NIVO)+5-fluorouracil/leucovorin/oxaliplatin (mFOLFOX6)/bevacizumab (BEV) versus mFOLFOX6/BEV for first-line (1L) treatment of metastatic colorectal cancer (mCRC): Phase 2 results from CheckMate 9X8
Heinz-Josef Lenz et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Phase II trial of cabozantinib (Cabo) plus durvalumab (Durva) in chemotherapy refractory patients with advanced mismatch repair proficient/microsatellite stable (pMMR/MSS) colorectal cancer (CRC): CAMILLA CRC cohort results
Anwaar Saeed et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Phase I/II study of regorafenib (rego) and pembrolizumab (pembro) in refractory microsatellite stable colorectal cancer (MSSCRC)
Afsaneh Barzi et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer A Randomized Clinical Trial
Niharika B. Mettu et al.
JAMA NETWORK OPEN (2022)
Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study
Luis A. Diaz et al.
LANCET ONCOLOGY (2022)
Neoadjuvant nivolumab, ipilimumab, and celecoxib in MMR-proficient and MMR-deficient colon cancers: Final clinical analysis of the NICHE study.
Yara L. Verschoor et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Rationale and design of REGINA, a phase II trial of neoadjuvant regorafenib, nivolumab, and short-course radiotherapy in stage II and III rectal cancer
Giacomo Bregni et al.
ACTA ONCOLOGICA (2021)
Regorafenib-Avelumab Combination in Patients with Microsatellite Stable Colorectal Cancer (REGOMUNE): A Single-arm, Open-label, Phase II Trial
Sophie Cousin et al.
CLINICAL CANCER RESEARCH (2021)
LEAP-005: A phase II multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors-Results from the colorectal cancer cohort
Carlos Gomez-Roca et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination
Jiali Yu et al.
NATURE MEDICINE (2021)
Activity of tumor-associated macrophage depletion by CSF1R blockade is highly dependent on the tumor model and timing of treatment
Sarah A. O'Brien et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)
The Tumour Vasculature as a Target to Modulate Leucocyte Trafficking
Yang Zhao et al.
CANCERS (2021)
Final result of phase IB study of regorafenib and nivolumab in mismatch repair proficient advanced refractory colorectal cancer
R. Kim et al.
ANNALS OF ONCOLOGY (2021)
Single-arm, phase 2 study of regorafenib plus nivolumab in patients with mismatch repair-proficient (pMMR)/microsatellite stable (MSS) colorectal cancer (CRC).
Marwan Fakih et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
A single-arm study on the efficacy and safety of regorafenib plus sintilimab as salvage-line treatments in non-MSI-H metastatic colorectal cancer.
Rui Liu et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Regorafenib enhances anti-PD1 immunotherapy efficacy in murine colorectal cancers and their combination prevents tumor regrowth
Dennis Doleschel et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2021)
Clinical Response to Immunotherapy Targeting Programmed Cell Death Receptor 1/Programmed Cell Death Ligand 1 in Patients With Treatment-Resistant Microsatellite Stable Colorectal Cancer With and Without Liver Metastases
Chongkai Wang et al.
JAMA NETWORK OPEN (2021)
Regorafenib plus toripalimab in patients with metastatic colorectal cancer: a phase Ib/II clinical trial and gut microbiome analysis
Feng Wang et al.
CELL REPORTS MEDICINE (2021)
Efficacy and safety of regorafenib or fruquintinib plus camrelizumab in patients with microsatellite stable and/or proficient mismatch repair metastatic colorectal cancer: an observational pilot study
Feng-E Jiang et al.
NEOPLASMA (2021)
Site-specific response patterns, pseudoprogression, and acquired resistance in patients with melanoma treated with ipilimumab combined with anti-PD-1 therapy
Ines Pires da Silva et al.
CANCER (2020)
Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164
Dung T. Le et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Evaluating the Polarization of Tumor-Associated Macrophages Into M1 and M2 Phenotypes in Human Cancer Tissue: Technicalities and Challenges in Routine Clinical Practice
Sharmilla Devi Jayasingam et al.
FRONTIERS IN ONCOLOGY (2020)
Relationship between MLH1, PMS2, MSH2 and MSH6 gene-specific alterations and tumor mutational burden in 1057 microsatellite instability-high solid tumors
Mohamed E. Salem et al.
INTERNATIONAL JOURNAL OF CANCER (2020)
Relationships Between Immune Landscapes, Genetic Subtypes and Responses to Immunotherapy in Colorectal Cancer
Emilie Picard et al.
FRONTIERS IN IMMUNOLOGY (2020)
Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal Cancer The Canadian Cancer Trials Group CO.26 Study
Eric X. Chen et al.
JAMA ONCOLOGY (2020)
Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers
Myriam Chalabi et al.
NATURE MEDICINE (2020)
Regorafenib and Nivolumab or Pembrolizumab Combination and Circulating Tumor DNA Response Assessment in Refractory Microsatellite Stable Colorectal Cancer
Chongkai Wang et al.
ONCOLOGIST (2020)
Immune Checkpoint Inhibitors in pMMR Metastatic Colorectal Cancer: A Tough Challenge
Federica Marmorino et al.
CANCERS (2020)
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer
T. Andre et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Tumor-Associated Macrophages in Tumor Immunity
Yueyun Pan et al.
FRONTIERS IN IMMUNOLOGY (2020)
Immunotherapy in colorectal cancer: rationale, challenges and potential
Karuna Ganesh et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2019)
The Intersection between Tumor Angiogenesis and Immune Suppression
Osama E. Rahma et al.
CLINICAL CANCER RESEARCH (2019)
Regorafenib Promotes Antitumor Immunity via Inhibiting PD-L1 and IDO1 Expression in Melanoma
Rui-Yan Wu et al.
CLINICAL CANCER RESEARCH (2019)
Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial
Cathy Eng et al.
LANCET ONCOLOGY (2019)
Molecular insight of regorafenib treatment for colorectal cancer
Hiroyuki Arai et al.
CANCER TREATMENT REVIEWS (2019)
Lesion-Level Response Dynamics to Programmed Cell Death Protein (PD-1) Blockade
Juan C. Osorio et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer
Michael J. Overman et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Targeting veGF/veGFR to Modulate Antitumor immunity
Ju Yang et al.
FRONTIERS IN IMMUNOLOGY (2018)
Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations
Jun Gong et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Targeting Tumor-Associated Macrophages as a Potential Strategy to Enhance the Response to Immune Checkpoint Inhibitors
Luca Cassetta et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2018)
Updates on immunotherapy for colorectal cancer
Aparna Kalyan et al.
JOURNAL OF GASTROINTESTINAL ONCOLOGY (2018)
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
Michael J. Overman et al.
LANCET ONCOLOGY (2017)
Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade
Martina Schmittnaegel et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy
Michael A. Cannarile et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition
Priti S. Hegde et al.
CLINICAL CANCER RESEARCH (2016)
Hypoxia and metabolic adaptation of cancer cells
K. L. Eales et al.
ONCOGENESIS (2016)
Pembrolizumab (MK-3475) for patients (pts) with advanced colorectal carcinoma (CRC): Preliminary results from KEYNOTE-028
B. H. O'Neil et al.
EUROPEAN JOURNAL OF CANCER (2015)
VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors
Thibault Voron et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2015)
Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial
Jin Li et al.
LANCET ONCOLOGY (2015)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
D. T. Le et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
Axel Grothey et al.
LANCET (2013)
CSF-1R inhibition alters macrophage polarization and blocks glioma progression
Stephanie M. Pyonteck et al.
NATURE MEDICINE (2013)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Multiple Effects of Angiopoietin-2 Blockade on Tumors
Claire E. Lewis et al.
CANCER CELL (2011)
Targeting the ANG2/TIE2 Axis Inhibits Tumor Growth and Metastasis by Impairing Angiogenesis and Disabling Rebounds of Proangiogenic Myeloid Cells
Roberta Mazzieri et al.
CANCER CELL (2011)
Angiopoietin 2 Stimulates TIE2-Expressing Monocytes To Suppress T Cell Activation and To Promote Regulatory T Cell Expansion
Seth B. Coffelt et al.
JOURNAL OF IMMUNOLOGY (2011)
Macrophages, innate immunity and cancer: balance, tolerance, and diversity
Alberto Mantovani et al.
CURRENT OPINION IN IMMUNOLOGY (2010)
Microsatellite Instability in Colorectal Cancer
C. Richard Boland et al.
GASTROENTEROLOGY (2010)
分享论文
